Jong Hyun Yoon1, Hee Jo Yang1, Jae Heon Kim1, Seung Whan Doo1, Won Jae Yang1, Jiyoung Hwang2, Seong Sook Hong2, Suyeon Park3, Dae Yeon Cho4. 1. Department of Urology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea; 2. Department of Radiology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea; 3. Department of Biostatistics, Soonchungyang University, College of Medicine, Seoul, Republic of Korea; 4. Department of Urology, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.
Abstract
INTRODUCTION: We sought to investigate the impact of fatty liver disease (FLD) on prostate cancer (PCa) screening by estimating the odds of having a prostate-specific antigen (PSA) value over the cutoff used to prompt for the recommendation of prostate biopsy. METHODS: Between 2007 and 2013, 18 533 native Korean men eligible to receive a serum PSA test, liver profiles, and abdominal ultrasonography were recruited. Logistic regression was used to estimate the odds of an abnormal PSA (≥2.5 ng/mL) in these men (age 45-75 years, PSA≤10 ng/mL) in relation to FLD. The FLD status was categorized as normal, mild, moderate, and severe grade by abdominal sonography. RESULTS: A total of 16 563 men (89.4%) were included in the study after applying the inclusion criteria. Liver profiles were negatively correlated with the serum PSA level. After controlling for age and obesity, there was a statistically significant trend towards a lower likelihood of having a serum PSA level of ≥2.5 ng/mL with severe FLD, having a 34.7% lower likelihood (odds ratio 0.653, 95% confidence interval 0.477-0.88; p<0.01) compared to men in the normal group. CONCLUSIONS: Severe FLD is an independent predictor of a lower likelihood of having abnormal PSA level. Further studies are needed to better define these results in clinical biopsy practice.
INTRODUCTION: We sought to investigate the impact of fatty liver disease (FLD) on prostate cancer (PCa) screening by estimating the odds of having a prostate-specific antigen (PSA) value over the cutoff used to prompt for the recommendation of prostate biopsy. METHODS: Between 2007 and 2013, 18 533 native Korean men eligible to receive a serum PSA test, liver profiles, and abdominal ultrasonography were recruited. Logistic regression was used to estimate the odds of an abnormal PSA (≥2.5 ng/mL) in these men (age 45-75 years, PSA≤10 ng/mL) in relation to FLD. The FLD status was categorized as normal, mild, moderate, and severe grade by abdominal sonography. RESULTS: A total of 16 563 men (89.4%) were included in the study after applying the inclusion criteria. Liver profiles were negatively correlated with the serum PSA level. After controlling for age and obesity, there was a statistically significant trend towards a lower likelihood of having a serum PSA level of ≥2.5 ng/mL with severe FLD, having a 34.7% lower likelihood (odds ratio 0.653, 95% confidence interval 0.477-0.88; p<0.01) compared to men in the normal group. CONCLUSIONS: Severe FLD is an independent predictor of a lower likelihood of having abnormal PSA level. Further studies are needed to better define these results in clinical biopsy practice.
Authors: N Masumori; T Tsukamoto; Y Kumamoto; H Miyake; T Rhodes; C J Girman; H A Guess; S J Jacobsen; M M Lieber Journal: J Urol Date: 1996-04 Impact factor: 7.450